PharVision Advisers’s PTC Therapeutics PTCT Stock Holding History

PharVision Advisers’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,934	Closed	-$299K	–	519
2025 Q4	$299K	Buy	+3,934	New	+$286K	0.15%	275

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

PharVision Advisers's PTCT Position: Q1 2026 in Review

PharVision Advisers sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 3,934 shares — an estimated $299K sold.

PharVision Advisers first reported a position in PTCT in Q4 2025 and held it in 1 quarter. The position peaked at $299K in Q4 2025. 352 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

PharVision Advisers reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 3,934 PTC Therapeutics shares in Q1 2026, an estimated $299K.
PharVision Advisers first reported a position in PTC Therapeutics in Q4 2025 and held it in 1 quarter.
PharVision Advisers's PTC Therapeutics position peaked at $299K in Q4 2025.
352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.